Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Atossa Therapeutics, Inc. develops clinical-stage medicines for oncology and other areas of unmet medical need. Its recurring news centers on (Z)-endoxifen, the company's lead product candidate, including breast cancer research, mammographic breast density data, and expansion into rare disease indications such as Duchenne muscular dystrophy and McCune-Albright Syndrome.
Company updates also cover FDA orphan and rare pediatric disease designations, clinical and preclinical data presentations, peer-reviewed publications, intellectual property developments, leadership additions, financial results, and capital-allocation commentary tied to Atossa's development strategy.
Atossa Therapeutics (NASDAQ: ATOS) announced positive interim results from its Phase 2 study of oral Endoxifen for breast cancer, reporting a statistically significant 74% reduction in tumor cell proliferation (p = 0.031) over 22 days. All six patients showed a decrease in Ki-67, a key proliferation marker, with levels dropping below 25%. The study, conducted in Australia, aims to enroll 25 patients, and successful results may lead to a Phase 3 study. There were no safety concerns noted, and patients reported fewer side effects compared to traditional therapies.